Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company donated RMB1 million worth of their most popular immune system boosting products to Shunchang General Hospital.
| NANPING, China, Feb. 4, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company donated RMB1 million worth of their most popular immune system boosting products to Shunchang General Hospital. Sales for the company’s nutraceutical supplement products targeted to enhance people’s immune system such as Cordyceps Mycelia Oral Liquid has skyrocketed over 100% since the Wuhan Novel Coronavirus (2019 -nCoV) outbreak in China. “We are experiencing a dramatic increase in market demand for our nutraceutical and dietary supplements that help improve resistance to infections, and we want to contribute and support the efforts against this outbreak. Our hope is that this donation helps Shunchang General Hospital in their efforts to combat and treat patients against the Novel Coronavirus (2019 - nCoV).” said Mr. Xuezhu Wang, CEO of the Company. About Happiness Biotech Group Limited. Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company’s goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 CFDA registered “Blue-Cap” SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
SOURCE Happiness Biotech Group Limited | ||
Company Codes: NASDAQ-NMS:HAPP |
View original content:
